

# Cecilie Blimark

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11844180/publications.pdf>

Version: 2024-02-01

22  
papers

1,433  
citations

567281

15  
h-index

713466

21  
g-index

22  
all docs

22  
docs citations

22  
times ranked

2213  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. <i>Haematologica</i> , 2015, 100, 107-113.	3.5	356
2	Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. <i>Blood</i> , 2010, 115, 4991-4998.	1.4	204
3	Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. <i>Blood</i> , 2009, 114, 791-795.	1.4	133
4	Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. <i>Haematologica</i> , 2012, 97, 854-858.	3.5	110
5	Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. <i>Haematologica</i> , 2009, 94, 1714-1720.	3.5	95
6	Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. <i>Blood</i> , 2010, 116, 2651-2655.	1.4	89
7	Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. <i>Haematologica</i> , 2018, 103, e412-e415.	3.5	87
8	Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. <i>Blood</i> , 2011, 118, 6284-6291.	1.4	74
9	Secondary immunodeficiency in lymphoproliferative malignancies. <i>Hematological Oncology</i> , 2016, 34, 121-132.	1.7	68
10	Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. <i>International Journal of Cancer</i> , 2009, 125, 2147-2150.	5.1	63
11	Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register. <i>European Journal of Haematology</i> , 2017, 99, 216-222.	2.2	48
12	Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population. <i>British Journal of Haematology</i> , 2014, 164, 684-693.	2.5	38
13	Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study. <i>Haematologica</i> , 2016, 101, e145-e148.	3.5	26
14	Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 183-193.	2.3	16
15	Melphalan 100 mg/m <sup>2</sup> with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation. <i>European Journal of Haematology</i> , 2011, 87, 117-122.	2.2	15
16	Real World Data In Myeloma: Experiences From The Swedish Population-Based Registry On 2494 Myeloma Patients Diagnosed 2008-2011. <i>Blood</i> , 2013, 122, 1972-1972.	1.4	4
17	Arterial and Venous Thrombosis in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Population-Based Study.. <i>Blood</i> , 2009, 114, 1872-1872.	1.4	2
18	Multiple Myeloma and Infections: A Population-Based Study Based On 9,610 Multiple Myeloma Patients. <i>Blood</i> , 2012, 120, 945-945.	1.4	2

#	ARTICLE	IF	CITATIONS
19	Lenalidomide versus lenalidomide+Âdexamethasone prolonged treatment after secondâ€line lenalidomide+Âdexamethasone induction in multiple myeloma. Cancer Medicine, 2018, 7, 2256-2268.	2.8	1
20	Is Multiple Myeloma a Chronic Disease? A Population Based Study Comparing 1843 Patients to a Matched Swedish Population.. Blood, 2012, 120, 2970-2970.	1.4	1
21	The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex. Blood, 2015, 126, 3047-3047.	1.4	1
22	Monoclonal Gammopathy of Undetermined Significance and Risk of Infections: A Population-Based Study. Blood, 2010, 116, 4053-4053.	1.4	0